Objective: To study the cellular immunoregulatory effect of Huangqi through intravenous injection in patients with chronic hepatitis B. Methods: In treated groups, light and mild chronic hepatitis B (15 patients in each group) were treated with Huangqi and Ganlixin. In control groups, 10 patients in each group with light and mild chronic hepatitis B were treated with Ganlixin. Normal control group included 10 healthy volunteers. Results: Compared with control group, the level of CD3 +, CD4 + and CD4 + /CD8 + in treatment group increased significantly ( P
Result Analysis
Print
Save
E-mail